BioSpace News Archive

Revolution Medicines, Inc. (Nasdaq: RVMD), today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 23rd Annual Global Investment Conference.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company approved the grant of equity awards to one new employee with a grant date of September 1, 2021, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at the virtual H.C. Wainwright 23rd Annual Global Investor Conference.

CONMED Corporation announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference at 5:00 p.m. ET on Tuesday, September 14, 2021.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Linda Marbán, Ph.D., Capricor’s CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

Ensemble Orthopedics Inc, a privately held company, today announced the 35th implantation of its interpositional CMC device for the treatment of carpometacarpal (CMC or thumb) osteoarthritis.

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it will be participating in two upcoming virtual investor conferences.

SciSparc Ltd. announced it has been awarded two patents from the Australian Patent Office and one from the Japanese Patent Office concerning the proprietary compounds and methods underlying the Company’s core technologies.

Therapeutic Solutions International, Inc., announced the signing of a memorandum of understanding with immunotherapy company Eutilogics, Inc., the wholly owned subsidiary of clinical stage Korean company, Eutilex Co., Ltd., based on exploring synergies between technologies of both Companies.